Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast

Histopathology

Volumn 53, Issue 4, 2008, Pages 403-415

  Gonzalez, L O ^a,b   Corte, M D ^a   Vazquez, J ^a,b   Junquera, S ^a   Sanchez, R ^a   Vina A ^a   Rodriguez, J C ^a,b   Lamelas, M L ^a,b   Vizoso, F ^a,b  

^a HOSPITAL DE JOVE   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Breast cancer; Ductal carcinoma in situ; Matrix metalloproteinase; Prognosis; Tissue arrays; Tissue inhibitor of metalloproteinase; Tumour invasion

Indexed keywords

COLLAGENASE 3; ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; PROGESTERONE RECEPTOR; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CLUSTER ANALYSIS; ENZYME INHIBITION; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR CELL;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 52649169669     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03136.x     Document Type: Article

References (79)

1. Ernster VL, Ballard-Barbash R, Barlow WE et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J. Natl Cancer Inst. 2002 94 1546 1554.
2. Bijker N, Rutgers EJ, Peterse JL et al. Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur. J. Surg. Oncol. 2001 27 135 140.
3. Fisher B, Bauer M, Margolese R et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N. Engl. J. Med. 1985 312 665 673.
4. Houghton J, George WD, Cuzick J et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003 362 95 102.
5. Julien JP, Bijker N, Fentiman IS et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000 355 528 533.
6. Fisher B, Dignam J, Wolmark N et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J. Clin. Oncol. 1998 16 441 452.
7. Adeyinka A, Emberley E, Niu Y et al. Analysis of gene expression in ductal carcinoma in situ of the breast. Clin. Cancer Res. 2002 8 3788 3795.
8. Nofech-Mozes S, Spayne J, Rakovitch E, Hanna W. Prognostic and predictive molecular markers in DCIS: a review. Adv. Anat. Pathol. 2005 12 256 264.
9. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 2000 18 1135 1149.
10. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002 21 2245 2252.
11. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br. J. Cancer 1999 79 1347 1355.
12. Guedez L, McMarlin AJ, Kingma DW et al. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am. J. Pathol. 2001 158 1207 1215.
13. Wurtz SO, Schrohl AS, Sorensen NM et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr. Relat. Cancer 2005 12 215 227.
14. Hagedorn HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review). Int. J. Oncol. 2001 18 669 681.
15. Bachmeier BE, Iancu CM, Jochum M, Nerlich AG. Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach. Expert Rev. Anticancer Ther. 2005 5 149 163.
16. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001 17 463 516.
17. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002 2 161 174.
18. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases) - on the main stage of cancer? Cancer Cell 2004 5 409 410.
19. Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. Proteolytic control of growth factor availability. APMIS 1999 107 80 85.
20. Manes S, Llorente M, Lacalle RA et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J. Biol. Chem. 1999 274 6935 6945.
21. Noe V, Fingleton B, Jacobs K et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 2001 114 111 118.
22. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001 3 459 468.
23. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000 14 163 176.
24. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 1999 103 1237 1241.
25. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997 88 801 810.
26. Cornelius LA, Nehring LC, Harding E et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 1998 161 6845 6852.
27. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000 486 247 251.
28. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J. Pathol. 1999 189 161 168.
29. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000 2 252 257.
30. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res. Treat. 2001 65 55 61.
31. Baker EA, Stephenson TJ, Reed MW, Brown NJ. Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol. Pathol. 2002 55 300 304.
32. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer 2003 89 1270 1275.
33. Grieu F, Li WQ, Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res. Treat. 2004 88 197 204.
34. Li HC, Cao DC, Liu Y et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res. Treat. 2004 88 75 85.
35. Sivula A, Talvensaari-Mattila A, Lundin J et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res. Treat. 2005 89 215 220.
36. Chantrain CF, Shimada H, Jodele S et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004 64 1675 1686.
37. Pellikainen JM, Ropponen KM, Kataja VV et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin. Cancer Res. 2004 10 7621 7628.
38. Vizoso FJ, Gonzalez LO, Corte MD et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br. J. Cancer 2007 96 903 911.
39. Mimori K, Ueo H, Shirasaka C, Mori M. Clinical significance of MT1-MMP mRNA expression in breast cancer. Oncol. Rep. 2001 8 401 403.
40. Nielsen BS, Rank F, Lopez JM et al. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res. 2001 61 7091 7100.
41. Ree AH, Florenes VA, Berg JP et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. 1997 3 1623 1628.
42. McCarthy K, Maguire T, McGreal G et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int. J. Cancer 1999 84 44 48.
43. Nakopoulou L, Giannopoulou I, Stefanaki K et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J. Pathol. 2002 197 307 313.
44. Schrohl AS, Christensen IJ, Pedersen AN et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol. Cell Proteomics 2003 2 164 172.
45. Schrohl AS, Holten-Andersen MN, Peters HA et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin. Cancer Res. 2004 10 2289 2298.
46. Visscher DW, Hoyhtya M, Ottosen SK et al. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int. J. Cancer 1994 59 339 344.
47. Remacle A, McCarthy K, Noel A et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int. J. Cancer 2000 89 118 121.
48. Polette M, Clavel C, Cockett M et al. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis 1993 13 31 37.
49. Lebeau A, Nerlich AG, Sauer U, Lichtinghagen R, Lohrs U. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res. 1999 19 4257 4264.
50. Kim HJ, Park CI, Park BW, Lee HD, Jung WH. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med. J. 2006 47 333 342.
51. Consensus conference on the classification of ductal carcinoma in situ. Hum. Pathol. 1997 28 1221 1225.
52. Silverstein MJ, Poller DN, Waisman JR et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995 345 1154 1157.
53. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998 11 155 168.
54. Parker RL, Huntsman DG, Lesack DW et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am. J. Clin. Pathol. 2002 117 723 728.
55. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. U.S.A. 1998 95 14863 14868.
56. Scorilas A, Karameris A, Arnogiannaki N et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer 2001 84 1488 1496.
57. Soini Y, Hurskainen T, Hoyhtya M, Oikarinen A. Autio-Harmainen H. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J. Histochem. Cytochem. 1994 42 945 951.
58. Nielsen BS, Sehested M, Kjeldsen L et al. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab. Invest. 1997 77 345 355.
59. Ponder BA. Cancer genetics. Nature 2001 411 336 341.
60. Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res. 2001 61 1320 1326.
61. Zhao YG, Xiao AZ, Park HI et al. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res. 2004 64 590 598.
62. Jiang WG, Davies G, Martin TA et al. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin. Cancer Res. 2005 11 6012 6019.
63. Wang F, Reierstad S, Fishman DA. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett. 2006 236 292 301.
64. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 1997 89 1260 1270.
65. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 1998 58 2310 2315.
66. Spurbeck WW, Ng CY, Strom TS, Vanin EF, Davidoff AM. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 2002 100 3361 3368.
67. Collen A, Hanemaaijer R, Lupu F et al. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood 2003 101 1810 1817.
68. Bachman KE, Herman JG, Corn PG et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999 59 798 802.
69. Zochbauer-Muller S, Fong KM, Virmani AK et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001 61 249 255.
70. Kang SH, Choi HH, Kim SG et al. Transcriptional inactivation of the tissue inhibitor of metalloproteinase-3 gene by DNA hypermethylation of the 5′-CpG island in human gastric cancer cell lines. Int. J. Cancer 2000 86 632 635.
71. Ueki T, Toyota M, Sohn T et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000 60 1835 1839.
72. Wild A, Ramaswamy A, Langer P et al. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J. Clin. Endocrinol. Metab. 2003 88 1367 1373.
73. Ahonen M, Ala-Aho R, Baker AH et al. Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol. Ther. 2002 5 705 715.
74. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J. Clin. Invest. 1998 101 1478 1487.
75. Smith MR, Kung H, Durum SK, Colburn NH, Sun Y. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 1997 9 770 780.
76. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000 1477 267 283.
77. Paquette B, Bisson M, Therriault H et al. Activation of matrix metalloproteinase-2 and -9 by 2- and 4-hydroxyestradiol. J. Steroid Biochem. Mol. Biol. 2003 87 65 73.
78. Di GH, Lu JS, Song CG et al. Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas. J. Exp. Clin. Cancer Res. 2005 24 601 607.
79. Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J. Pathol. 1997 181 200 206.